Patents by Inventor Christine Favre

Christine Favre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Suppression of Bone Cancer-induced Allodynia
    Publication number: 20210205422
    Abstract: The present invention provides a method for suppressing bone cancer-induced allodynia in a patient, said method comprising administration of a therapeutically effective amount of a non-cytotoxic protease to a patient suffering from bone cancer.
    Type: Application
    Filed: May 21, 2019
    Publication date: July 8, 2021
    Inventors: Mikhail KALINICHEV, Christine FAVRE
  • Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy
    Patent number: 9259458
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 16, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
  • Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative
    Patent number: 9080220
    Abstract: The present invention relates to a composition comprising: at least one botulinum neurotoxin, and at least one opiate derivative or its salt. The invention also relates to a product comprising at least one botulinum neurotoxin and at least one opiate derivative or its salt, as a combination product for simultaneous, separate or sequential therapeutic use in the treatment or prevention of pain and of neuromuscular disorders.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: July 14, 2015
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Michel Auguet, Christine Favre, Pierre-Etienne Chabrier De Lassauniere
  • Use of at least one botulinum neurotoxin for treating the pain induced by therapeutic treatments for the AIDS virus
    Patent number: 8921322
    Abstract: The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: December 30, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere
  • Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy
    Patent number: 8784841
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: July 22, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
  • Therapeutic Use of Botulinum Neurotoxin in the Treatment of pain associated with diabetic neuropathy
    Publication number: 20140154781
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Christine FAVRE, Michel AUGUET, Piere-Etienne CHABRIER DE LASSAUNIERE
  • Therapeutic use of at least one botulinum neurotoxin in the treatment of pain induced by at least one anti-neoplastic agent
    Patent number: 8273359
    Abstract: The present invention relates to a method of treating or preventing pain or pains induced by an anti-neoplastic agent, comprising the step of administering an effective amount of at least one botulinum neurotoxin to a patient in need thereof.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: September 25, 2012
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere
  • THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN IN THE TREATMENT OF PAIN ASSOCIATED WITH DIABETIC NEUROPATHY
    Publication number: 20110038893
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Application
    Filed: April 27, 2009
    Publication date: February 17, 2011
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
  • Therapeutic use of at least one botulinum neurotoxin in the treatment of pain induced by at least one anti-neoplastic agent
    Publication number: 20100068231
    Abstract: The present invention relates to a method of treating or preventing pain or pains induced by an anti-neoplastic agent, comprising the step of administering an effective amount of at least one botulinum neurotoxin to a patient in need thereof.
    Type: Application
    Filed: October 26, 2007
    Publication date: March 18, 2010
    Inventors: Christine Favre, Michel Auguet, Pierrre-Etienne Chabrier De Lassauniere
  • USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR TREATING THE PAIN INDUCED BY THERAPEUTIC TREATMENTS FOR THE AIDS VIRUS
    Publication number: 20100029566
    Abstract: The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus.
    Type: Application
    Filed: December 17, 2007
    Publication date: February 4, 2010
    Applicant: IPSEN PHARMA S.A.S
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere
  • USE OF A DIHYDROIMIDAZOPYRAZOINE DERIVATIVE FOR TREATING OR PREVENTING PAIN
    Publication number: 20090270401
    Abstract: The invention relates to the use of (1R)-1-[({(2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-yl]-2-oxoethylamine or an pharmaceutically acceptable salt thereof for preparing a drug for preventing or treating pain.
    Type: Application
    Filed: December 16, 2005
    Publication date: October 29, 2009
    Applicant: Societe de Conseils de Recherches et D'Applications Sceintifiques (S.C.R.A.S.)
    Inventors: Michel Auguet, Christine Favre, Gregoire Prevost
  • PAINKILLING ASSOCIATION COMPRISING A DIHYDROIMIDAZOPYRAZINE DERIVATIVE
    Publication number: 20090270400
    Abstract: The invention relates to a product comprising (1R)-1-[(({2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl) -2-phenyl-5,6-dihydroimidazo [1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl) -2-phenyl-5,6-dihydrolmidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine in association with an analgesic agent selected from morphine, the similar or a morphine derivative, sodium channel inhibitors, non-steroidal antiflammatory agents (AINS), glutamatergic system inhibitors, tricycle antidepressants and gabaergic derivatives for simultaneous therapeutic use which is separated or out over the time for pain treatment or prevention.
    Type: Application
    Filed: December 16, 2005
    Publication date: October 29, 2009
    Applicant: Societe de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.)
    Inventors: Michel Auguet, Christine Favre, Gregoire Prevost, Pierre-Etienne Chabrier De Lassauniere
  • SIMULTANEOUS, SEPARATE OR SEQUENTIAL THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN AND OF AT LEAST ONE OPIATE DERIVATIVE
    Publication number: 20090232851
    Abstract: The present invention relates to a composition comprising: at least one botulinum neurotoxin, and at least one opiate derivative or its salt. The invention also relates to a product comprising at least one botulinum neurotoxin and at least one opiate derivative or its salt, as a combination product for simultaneous, separate or sequential therapeutic use in the treatment or prevention of pain and of neuromuscular disorders.
    Type: Application
    Filed: June 11, 2007
    Publication date: September 17, 2009
    Inventors: Michel Auguet, Christine Favre, Pierre-Etienne Chabrier De Lassauniere